Despite growing recognition of TREM-1 as an emerging target in cancer (3, 4) and other inflammatory diseases and disorders (reviewed in (5–9), the question whether pan-TREM-1 and cell-restricted TREM-1 (e.g., macrophage-restricted) inhibitors can differ in their therapeutic potential has never been addressed mainly due to the lack of proper methodology. This evidence concerns the gene TREM1 and cancer.